Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors
Summary
USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.
What changed
USPTO issued Patent No. US12595234B2 granting the Council of Scientific & Industrial Research exclusive rights to functionalized benzocycloheptene analogues derived from himachalenes. The granted claims cover compounds that inhibit PI3K and MK2 enzymes, with potential therapeutic applications including anti-diabetic, antipyretic, anti-inflammatory, antiepileptic, anticancer, antiulcer, CNS-stimulant, and CNS-depressant treatments. The patent was filed on October 19, 2021, with Application No. 18032732.
Patent holders and licensees should verify the scope of the 10 granted claims relative to their existing IP portfolios and product development plans. Generic pharmaceutical manufacturers should assess whether their compound development programs could infringe these claims. The patent expires 20 years from the 2021 filing date, establishing a clear IP barrier for competing therapies targeting PI3K/MK2 pathways.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Bioactive benzocycloheptene analogues from himachalenes and its applications
Grant US12595234B2 Kind: B2 Apr 07, 2026
Assignee
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Inventors
Pralay Das, Yamini, Richa Bharti, Shankar Ram, Vijay Kumar Bhardwaj, Rituraj Purohit, Damanpreet Singh, Prince Anand, Yogendra S Padwad
Abstract
Functionalized benzocycloheptenes are one of the most important classes of bicyclic framework that have been investi-gated in different areas of biological activities. The claimed invention provides preparations of benzocycloheptene analogues, inhibitors of PI3K and MK2, pharmaceutical compositions containing them and their use in therapy. The compounds of Formula I, II, III, IV, V and VI may be used as anti type 2 diabetes, antipyretic, anti-inflammatory, antiepileptic, anticancer, antiulcer, CNS-stimulant, and CNS-depressant. These benzocycloheptene derivatives are useful in treatment of PI3K and MK2 related disorders.
CPC Classifications
C07D 209/94 C07D 221/18 C07D 307/93 C07C 311/16 C07C 317/10 C07C 317/14 C07C 2602/12
Filing Date
2021-10-19
Application No.
18032732
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.